# Revolutionary Finger-Prick Test for Alzheimer's Validation! Newsy: Alzheimer’s News Weekly Published: 2026-01-19T13:30:00.525Z Source: https://newsyai.com/edition/9dc73784-9af9-4c9d-80eb-b4eb4c960552 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # Alzheimer’s Treatment Briefing Coverage period: January 13–19, 2026 Below are the most meaningful, truly new developments from the past 7 days, ranked by impact on treatment and access. ## Top stories (ranked) 1) Finger‑prick blood test for Alzheimer’s enters large, international validation - Overview - LifeArc and the Global Alzheimer’s Platform Foundation announced a major project within the BIO‑HERMES‑002 study to validate a simple finger‑prick “dried blood spot” test that measures three key proteins linked to Alzheimer’s (p‑tau217, GFAP, NfL). Samples can be mailed without refrigeration. As of January 19, 883 of the planned 1,000 participants have enrolled across 25 sites in the U.S., UK, and Canada. Completion is targeted for 2028. ([lifearc.org](https://www.lifearc.org/2026/finger-prick-blood-test-alzheimers-disease/?utm_source=openai)) - Why this matters - Making accurate screening as easy as a finger‑prick could greatly widen access to today’s and tomorrow’s treatments by allowing faster, cheaper triage outside specialty centers. It also supports more inclusive recruiting for trials by reducing travel and clinic barriers. ([lifearc.org](https://www.lifearc.org/2026/finger-prick-blood-test-alzheimers-disease/?utm_source=openai)) 2) Remote, at‑home collection shows strong promise for Alzheimer’s blood biomarkers - Overview - Independent of the new LifeArc effort, a multi‑center study (DROP‑AD) reported that finger‑prick blood collected at home and dried on cards can accurately measure Alzheimer’s biomarkers. In 337 people across seven European centers, dried‑spot p‑tau217 closely tracked standard blood tests and spinal‑fluid changes, with about 86% accuracy for detecting Alzheimer‑type changes. ([nationalhealthexecutive.com](https://www.nationalhealthexecutive.com/articles/finger-prick-blood-test-shows-promise-detecting-alzheimers?utm_source=openai)) - Why this matters - This is early but practical proof that remote testing can work. If adopted, it could shrink wait times, bring screening to rural and underserved communities, and streamline monitoring for people already on therapy. ([nationalhealthexecutive.com](https://www.nationalhealthexecutive.com/articles/finger-prick-blood-test-shows-promise-detecting-alzheimers?utm_source=openai)) 3) Fresh modeling links poor brain blood flow and amyloid buildup—pointing to combo‑therapy ideas - Overview - A new whole‑brain computer model published January 13 simulates how reduced blood flow and amyloid may fuel each other. It suggests that once a certain “seed” level is reached, disease can tip into a self‑sustaining state. The work supports the “two‑hit” idea: vascular problems can trigger amyloid changes, and vice versa. ([arxiv.org](https://arxiv.org/abs/2601.08478?utm_source=openai)) - Why this matters - While not a clinical trial, the insight backs real‑world strategies: pair plaque‑clearing drugs with aggressive control of vascular risks (blood pressure, sleep apnea, diabetes) and potentially future medicines that improve brain blood flow. It also underscores starting treatment earlier, before a self‑reinforcing cycle takes hold. ([arxiv.org](https://arxiv.org/abs/2601.08478?utm_source=openai)) 4) U.S. public health playbook for brain health gets an update - Overview - The Alzheimer’s Association released a special supplement in The Gerontologist (January 14) summarizing 20 years of U.S. public health progress on dementia, accelerated by the BOLD Act. It highlights risk‑reduction, earlier detection, and caregiver support becoming standard public‑health functions. ([alz.org](https://www.alz.org/news/2026/alzheimers-association-marks-20-years-of-public-health-progress-in-gerontologist-supplement?utm_source=openai)) - Why this matters - Stronger public‑health infrastructure makes it easier to roll out blood tests, route people to treatment centers, and support families as access to disease‑modifying drugs expands. Policy and implementation matter for who actually receives therapy—not just whether a drug exists. ([alz.org](https://www.alz.org/news/2026/alzheimers-association-marks-20-years-of-public-health-progress-in-gerontologist-supplement?utm_source=openai)) ## What this means for care right now - Expect faster, broader triage - The push toward finger‑prick testing (both the new BIO‑HERMES‑002 effort and the DROP‑AD data) could shorten the path from “concern” to “confirmed risk,” helping clinics prioritize who needs brain scans or treatment discussions first. ([lifearc.org](https://www.lifearc.org/2026/finger-prick-blood-test-alzheimers-disease/?utm_source=openai)) - Prepare for at‑home and hybrid workflows - Remote collection reduces clinic bottlenecks and can enable steadier monitoring once on therapy. Health systems should start mapping how to handle mailed‑in samples, result turnarounds, and follow‑up. ([nationalhealthexecutive.com](https://www.nationalhealthexecutive.com/articles/finger-prick-blood-test-shows-promise-detecting-alzheimers?utm_source=openai)) - Keep managing vascular health alongside disease‑modifying drugs - The new brain model strengthens the case for pairing anti‑amyloid treatments with rigorous control of blood pressure, diabetes, sleep, and exercise—practical steps that may enhance and prolong benefits. ([arxiv.org](https://arxiv.org/abs/2601.08478?utm_source=openai)) Sources - LifeArc/GAP press materials on finger‑prick validation within BIO‑HERMES‑002, January 19, 2026. ([lifearc.org](https://www.lifearc.org/2026/finger-prick-blood-test-alzheimers-disease/?utm_source=openai)) - National Health Executive: DROP‑AD finger‑prick home collection study summary, January 7, 2026; The Times coverage referencing Nature Medicine results. ([nationalhealthexecutive.com](https://www.nationalhealthexecutive.com/articles/finger-prick-blood-test-shows-promise-detecting-alzheimers?utm_source=openai)) - arXiv preprint: Whole‑brain model linking amyloid and low blood flow, January 13, 2026. ([arxiv.org](https://arxiv.org/abs/2601.08478?utm_source=openai)) - Alzheimer’s Association news release on public‑health supplement, January 14, 2026. ([alz.org](https://www.alz.org/news/2026/alzheimers-association-marks-20-years-of-public-health-progress-in-gerontologist-supplement?utm_source=openai)) If a week brings no truly new, treatment‑relevant developments, I will skip or shorten sections rather than repeat prior items.